To confirm the role of GSDMD, the RCN1‐deficient AML cells were treated with disulfiram (DSF), a specific inhibitor of acetaldehyde dehydrogenase type 1 (ALDH1) and effectively inhibits GSDMD pore formation. Here, GSDMD is linked to acute myeloid leukemia.